Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults
NCT04809389Phase 1Unknown
- Sponsor
- The University of Hong Kong
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Pneucolin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by The University of Hong Kong. Primary endpoint: Cumulative incidence of reactogenicity. Status: unknown.
02
Drugs
Pneucolin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04809389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04809389.